<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154712">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907191</url>
  </required_header>
  <id_info>
    <org_study_id>13-06-002</org_study_id>
    <nct_id>NCT01907191</nct_id>
  </id_info>
  <brief_title>Ultrasound Guided Local Infiltration Analgesia for Hip Arthroscopy</brief_title>
  <official_title>Comparison of Bupivacaine to Liposomal Bupivacaine for Ultrasound Guided Periarticular Hip Infiltration for Postoperative Analgesia After Hip Arthroscopy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Francis Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Francis Care</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being undertaken to compare the pain control using either bupivacaine versus
      liposomal bupivacaine. Liposomal bupivacaine can potentially provide pain relief lasting up
      to 72 hours while regular bupivacaine can provide pain relief up to 12 hours
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>96 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Opioid consumption will be reviewed at 96 hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>96 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of pain scores (at rest and ambulation) during hospital stay.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sleep disturbance</measure>
    <time_frame>96 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of sleep disturbance during hospital stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Satisfaction with pain management</measure>
    <time_frame>96 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of pain management satisfaction during hospital stay</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Arthroscopy</condition>
  <condition>Hip Injuries</condition>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound guided injection of liposomal bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine (around the anterior, lateral and medial aspect of hip joint)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal bupivacaine</intervention_name>
    <description>(Ultrasound guided injection of liposomal bupivacaine)</description>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>(around the anterior, lateral and medial aspect of hip joint)</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having hip arthroscopy

        Exclusion Criteria:

          -  History of neurologic disease, neuropathy, diabetes

          -  Allergy to local anesthetic solution

          -  Chronic use of narcotics

          -  Inability to give consent/cooperate with study

          -  History of previous hip arthroscopy on the ipsilateral side

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Sinha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Francis Hospital and Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjay Sinha, MD</last_name>
    <email>sanjaysinha@comcast.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Francis Hospital and Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Sinha, MD</last_name>
      <email>sanjaysinha@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Sanjay Sinha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>June 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip Arthroscopy</keyword>
  <keyword>Liposomal Bupivacaine</keyword>
  <keyword>Bupivacaine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hip Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
